FGBweb_BFGBweb_BFGBweb_BFGBweb_B
  • THE FOUNDATION
    • About Us
    • Background
    • Our Mission
    • Contact Us
  • PROGRAMS
    • Fellowships
    • Research
  • NEWS & UPDATES
    • News
    • Press Area
  • VIDEO
English
  • Italiano
✕
Activity of olaparib in patients with BRCA-mutated early breast cancer
27/06/2022
Efficacy of nivolumab as neoadjuvant therapy in resectable lung cancer
11/07/2022

Neratinib and fulvestrant are active for HER2-mutated metastatic breast cancer

Published by Fondazione Gianni Bonadonna at 04/07/2022
Categories
  • Events
  • Uncategorized
Tags

The phase II MutHER study shows that neratinib in combination with fulvestrant has antitumor activity in patients with metastatic estrogen receptor-positive and HER-2 mutated breast cancer

A new study published on Clinical Cancer Research shows that a combination of the irreversible pan-HER inhibitor neratinib with the anti-HER2 fulvestrant is active in metastatic estrogen receptor-positive and HER-2 mutated, non amplified breast cancer, regardless of prior treatment with a CDK4/6 inhibitor.

MutHER study, a single-arm multi-cohort phase II trial, enrolled 40 patients with a stage IV breast cancer and a median of three prior treatments. It comprised three cohorts: estrogen receptor positive and fulvestrsant naïve (11), estrogen receptors positive and fulvestrant treated (24), estrogen receptor negative (5). The median progression free survival after neratinib in combination with fulvestrant was 24 months in the fulvestrant-treated group, 20 in the fulvestrant-naïve group, and 8.5 in the estrogen receptor-negative group; the clinical benefit rate was 38%, 30% and 25% in the three cohorts, respectively, and the most common grade 3 adverse event was diarrhea in 25% of patients. Sensitivity to neratinib may be influenced by breast cancer histology and HER2 mutation location: lobular histology was particularly responsive to the treatment, while HER2 L755 alterations were associated with less efficacy; moreover, response to therapy was accompanied by early decreases in HER2 mutation variant allele frequency and progression was associated with acquired HER2 mutations, demonstrating the value of serial circulating tumor DNA monitoring. Adding trastuzumab at progression in 5 patients resulted in three partial responses and one stable disease, suggesting dual HER2 blockade may be important in targeting HER2 mutation. «Further investigation of trastuzumab in combination with neratinib is therefore warranted», authors conclude.

Share
1

Related posts

Cancer Treatment - Medical Concept with Blurred Text, Stethoscope, Pills and Syringe on Red Background. Selective Focus. 3D Render.

18/09/2023

SHP2 inhibition to overcome resistance to targeted therapies


Read more

Medical supplies on light background. Concept of cancer research

11/09/2023

Dostarlimab in primary advanced or recurrent endometrial cancer


Read more
08/09/2023

Is it possible to predict the efficacy of immunotherapy in triple-negative breast cancer?


Read more

Follow us

LinkedIn | Facebook | Twitter
  • Privacy policy
  • Cookie policy
© 2021 - Fondazione Gianni Bonadonna
    English
    • Italiano
    • English